BMS-582949 hydrochloride is an orally active and highly selective p38α MAPK inhibitor, with an IC50 of 13 nM. BMS-582949 hydrochloride displays a significantly improved pharmacokinetic profile and is effective in inflammatory disease.
体外研究
BMS-582949 displays a p38α IC50 of 13 nM and a cellular TNFα IC50 of 50 nM.
BMS-582949 is a weak inhibitor of CYP3A4 BMS-582949 displays >2000-fold selectivity for p38α over a diverse panel of 57 kinases that include serine kinases, nonreceptor tyrosine kinases, receptor tyrosine kinases, and the p38γ and δ isoforms.
体内研究
BMS-582949 (5-100 mg/kg, orally) is effective in both the acute murine model of inflammation and rat adjuvant arthritis model despite its slightly reduced potency.
Animal Model:
Male Sprague-Dawley rats (250-300 g) adjuvant arthritis model.
Dosage:
1, 10, 100 mg/kg.
Administration:
Orally once daily (from day 11 to day 19).
Result:
Displayed dose-dependent reduction in paw swelling with qd dosing, with efficacy observed at doses of 10 and 100 mg/kg.
分子式
C22H27ClN6O2
分子量
442.94
CAS号
912806-16-7
运输条件
Room temperature in continental US; may vary elsewhere.